Tate & Lyle reported a 3% revenue decline and 6% EBITDA decline, meeting expectations. Shares rose 5% as cost synergies were realized faster than expected. The company is well-positioned to benefit from long-term reformulation trends in food and beverages. With an EBITDA margin of 21%, Tate & Lyle outperforms larger peers.

The company is ahead of plan on CP Kelco integration, delivering $30 million in cost synergies by the end of first half fiscal 2026. Despite short-term challenges, shares appear substantially undervalued and trade in 5-star territory. Investor sentiment has turned negative in the ingredients sector, but long-term opportunities are being overlooked.

Reaffirming a fair value estimate of GBX 725 for Tate & Lyle. Market overemphasizes short-term challenges, overlooking long-term opportunities in reformulation, innovation, and focus on higher-margin specialty ingredients. Integration risk post-CP Kelco acquisition is a concern, but the company is poised for organic growth acceleration.

Read more at Morningstar: Tate & Lyle Earnings: Cost Synergies Ahead of Plan, Shares Rebound Mid-Single-Digits but Remain Cheap